ESPR רווח למניה בשנים עשר החודשים האחרונים Esperion Therapeutics, Inc.

Annual net income per share demonstrates the resilience of Esperion Therapeutics (ESPR), despite geopolitical risks and challenges with international patenting. The company is capturing the non-statin cholesterol-fighting niche, creating an affordable alternative to injections. However, pressure from insurers limits pricing power, and -0.10 represents the current metric value.

This indicator calculates the net income distributed per common share over a rolling year, allowing for an assessment of real capital efficiency without issuance distortions. By analyzing the rolling 12-month earnings per share, an investor can see how licensing fees from Nexletol partnerships and the M&A activity of Esperion Therapeutics (ESPR) translate into concrete financial returns for every shareholder.